Home Cart Sign in  
Chemical Structure| 2212020-52-3 Chemical Structure| 2212020-52-3

Structure of Orforglipron
CAS No.: 2212020-52-3

Chemical Structure| 2212020-52-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Orforglipron is an orally active GLP-1 receptor agonist that promotes insulin secretion and suppresses appetite, widely used in research on diabetes and obesity-related metabolic diseases, with detailed information available in patent WO2018056453A1.

Synonyms: LY3502970; GLP-1 receptor agonist 1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Orforglipron

CAS No. :2212020-52-3
Formula : C48H48F2N10O5
M.W : 882.96
SMILES Code : C[C@H]1C[C@@]1(N2C(C(N3CCC4=NN(C(N5C=CN(C5=O)C6=CC=C7N(C)N=CC7=C6F)=C4[C@@H]3C)C8=CC(C)=C(F)C(C)=C8)=O)=CC9=CC([C@]%10(CCOC(C)(C)C%10)[H])=CC=C29)C%11=NOC(N%11)=O
Synonyms :
LY3502970; GLP-1 receptor agonist 1
MDL No. :MFCD31807602

Safety of Orforglipron

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Orforglipron

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06440980 Healthy|Obese|Overweight|Obesi... More >>ty Less << PHASE1 RECRUITING 2025-05-25 Anaheim Clinical Trials, LLC, ... More >>Anaheim, California, 92801, United States|Collaborative Neuroscience Research, LLC, Los Alamitos, California, 90720, United States|Fortrea Clinical Research Unit, Daytona Beach, Florida, 32117, United States|Altasciences Company Inc., Overland Park, Kansas, 66212, United States|QPS, Springfield, Missouri, 65802, United States|Fortrea Clinical Research Unit, Dallas, Texas, 75247, United States|Fortrea Clinical Research Unit, Madison, Wisconsin, 53704, United States Less <<
NCT05313802 Healthy|Obese PHASE1 COMPLETED 2022-09-09 Qps-Mra, Llc, Miami, Florida, ... More >>33143, United States|ICON Early Phase Services Lenexa Center, Lenexa, Kansas, 66219, United States|ICON Early Phase Services, San Antonio, Texas, 78209, United States Less <<
NCT05882032 Healthy|Hepatic Insufficiency PHASE1 COMPLETED 2024-11-18 Clinical Pharmacology of Miami... More >>, Miami, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Texas Liver Institute, San Antonio, Texas, 78215, United States|Pinnacle Clinical Research, San Antonio, Texas, 78229, United States Less <<
NCT05341089 Healthy PHASE1 COMPLETED 2022-09-01 Lilly Centre for Clinical Phar... More >>macology, Singapore, 138623, Singapore Less <<
NCT05110794 Healthy PHASE1 COMPLETED 2022-02-10 Lilly Centre for Clinical Phar... More >>macology, Singapore, 138623, Singapore Less <<
NCT06010004 Type 2 Diabetes PHASE3 ACTIVE_NOT_RECRUITING 2025-06-25 Nakayama Clinic, Nagoya, Aichi... More >>, 456-0058, Japan|Shinkashiwa Clinic, Kashiwa, Chiba, 277-0084, Japan|Kashiwa City Hospital, Kashiwa, Chiba, 277-0825, Japan|Tokuyama Clinic, Mihama-ku,Chiba City, Chiba, 261-0004, Japan|Mikannohana Clinic, Diabetes, Endocrinology and Metabolism, Matsuyama, Ehime, 790-0034, Japan|Steel Memorial Yawata Hospital, Kitakyushu, Fukuoka, 805-8508, Japan|Hasegawa Medical Clinic, Chitose, Hokkaido, 066-0032, Japan|Odori Diabetes, Sapporo, Hokkaido, 060-0001, Japan|Matsuda Clinic, Kobe, Hyogo, 651-2135, Japan|Nakamoto Internal Medicine Clinic, Mito, Ibaraki, 310-0826, Japan|MinamiAkatsukaClinic, Mito, Ibaraki, 311-4153, Japan|Nakakinen clinic, Naka, Ibaraki, 311-0113, Japan|Nishiyamadou Keiwa Hospital, Naka, Ibaraki, 311-0133, Japan|Taya Clinic Koueikai Medical Corporation, Tsuchiura, Ibaraki, 300-0047, Japan|Takai Internal Medicine Clinic, Kamakura-shi, Kanagawa, 247-0056, Japan|Shonan Takai Clinic, Kamakura, Kanagawa, 247-0055, Japan|Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi, Kanagawa, 242-0004, Japan|Yokohama Minoru Clinic, Yokohama, Kanagawa, 232-0064, Japan|Yokkaichi Diabetes Clinic, Yokkaichi, Mie, 510-0829, Japan|Gibo Hepatology Clinic, Matsumoto, Nagano, 399-0036, Japan|Shiraiwa Medical Clinic, Kashiwara, Osaka, 582-0005, Japan|Kitada Clinic, Osaka-city, Osaka, 538-0044, Japan|Medical Corporation Heishinkai OCROM Clinic, Suita-shi, Osaka, 565-0853, Japan|OHAMA Diabetes Clinic, Kawaguchi, Saitama, 332-0015, Japan|Sugiura Internal Medicine Clinic, Soka, Saitama, 340-0015, Japan|Seiwa Clinic, Adachi-ku, Tokyo, 120-0011, Japan|The Institute for Adult Disease, Asahi Life Foundation, Chuo-ku, Tokyo, 103-0002, Japan|Tokyo-Eki Center-building Clinic, Chuo-ku, Tokyo, 103-0027, Japan|Fukuwa Clinic, Chuo-ku, Tokyo, 104-0031, Japan|Hachioji Diabetes Clinic, Hachioji-shi, Tokyo, 192-0083, Japan|Kanno Naika, Mitaka, Tokyo, 181-0013, Japan|Heishinkai Medical Group ToCROM Clinic, Shinjuku-ku, Tokyo, 160-0008, Japan|Medical Corporation Tao Internal Medicine Clinic, Ube, Yamaguchi, 755-0047, Japan|Fujii Clinic, Ube, Yamaguchi, 755-0049, Japan|Tashiro Endocrinology Clinic, Fukuoka, 814-0153, Japan|Morinaga Ueno Clinic, Kumamoto, 860-0863, Japan|Jinnouchi Hospital, Kumamoto, 862-0976, Japan|Heiwadai Hospital, Miyazaki, 880-0034, Japan|Abe Clinic, Oita, 870-0039, Japan|Kansai Electric Power Hospital, Osaka, 553-0003, Japan Less <<
NCT06692348 Healthy PHASE1 RECRUITING 2025-08-25 Medical Corporation Heishinkai... More >> OPHAC Hospital, Osaka-shi, Osaka, 532-0003, Japan|Sumida Hospital, Sumida-ku, Tokyo, 130-0004, Japan|Hakata Clinic, Fukuoka, 812-0025, Japan Less <<
NCT05841238 Healthy|Obese PHASE1 COMPLETED 2023-11-13 LabCorp CRU, Inc., Daytona Bea... More >>ch, Florida, 32117, United States|Labcorp Clinical Research LP, Dallas, Texas, 75247, United States|LabCorp CRU, Inc., Madison, Wisconsin, 53704, United States Less <<
NCT05936138 Renal Insufficiency|Healthy PHASE1 COMPLETED 2024-04-11 Clinical Pharmacology of Miami... More >>, Miami, Florida, 33014, United States|Advanced Pharma CR, LLC, Miami, Florida, 33147, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Alliance For multispecialty Research, LLC, Knoxville, Tennessee, 37920, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.13mL

0.23mL

0.11mL

5.66mL

1.13mL

0.57mL

11.33mL

2.27mL

1.13mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories